A prospective study on the prevalence of neonatal alloimmune thrombocytopenia with maternal and neonatal human platelet antigen genotypic profiling.
4 affiliations
- 1Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- 2Department of Advanced Pediatric Centre, Head of Neonatalogy Unit, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- 3Department of Advanced Pediatric Centre, C Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- 4Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Abstract
Neonatal alloimmune thrombocytopenia (NAIT) results due to the human platelet antigen (HPA) incompatibility between the mother and the fetus, which in turn leads to maternal alloimmunization against fetal platelet antigen. In view of the lack of a defined protocol for its diagnosis and management, it is important to identify at-risk patients with the help of new noninvasive methods and prevent fetal complications. The aim of our study was to evaluate the suspected cases of NAIT so as to determine its prevalence and formulate an appropriate algorithm for its diagnosis and management in our setup. Thrombocytopenic neonates from neonatal services were included in the study between May 2018 and March 2020. An algorithm was designed to evaluate the suspected cases of NAIT, which involved the clinical assessment of the neonate and maternal HPA antibody screening and compatibility test with the neonatal platelet antigens by maternal serum on a solid phase red cell adherence assay system by Immucor, Norcoss A, USA. In addition, genotypic analysis was done to find out the implicated HPA antigens present in the neonate, causing NAIT. The genotypic assessment was done using the Link Seq HPA Typing Kit, by One Lambda, and real-time polymerase chain reaction. Out of 6237 neonates screened for eligibility, we found 1143 neonates to be thrombocytopenic. Out of 1143 thrombocytopenic neonates, we diagnosed NAIT in 10 neonates, giving a prevalence of 0.8% in thrombocytopenic neonates and 0.16% in the total enrolled neonates. The prevalence of NAIT in neonates with thrombocytopenia was 0.8%, and 0.16% in the total admitted neonates. HPA-3b, Hpa-9b and HPA-15b were found to be the most commonly implicated antigens leading to thrombocytopenia in the neonates, in our population.
Related
- PO036 | EVALUATION OF BREAST MILK AS A POTENTIAL MEDIATOR FOR THE TRANSFER OF MATERNAL ANTI-PLATELET ALLOANTIBODIES IN FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
- Prevalence, severity, and associated factors of thrombocytopenia among pregnant women attending antenatal care clinic in North West Ethiopia,2024: cross-sectional study
- Associations of Thrombocytopenia and Subthreshold Platelet Counts with Clinical Outcomes in Intensive Care Patients: A Prospective Cohort Study
- Prevalence and Pattern of Thyroid Dysfunction Among Women of Reproductive Age With Abnormal Uterine Bleeding: A Prospective Observational Study
- Prevalence and incidence of myopia among children and adolescents aged 6–19 years: a prospective cohort study
BibTeX
@article{sharma2026prospective,
title = {{A prospective study on the prevalence of neonatal alloimmune thrombocytopenia with maternal and neonatal human platelet antigen genotypic profiling.}},
author = {Greeshma Sharma and Ratti Ram Sharma and Praveen Kumar and Rekha Hans and Prateek Bhatia and Shano Naseem and Divjot Singh Lamba},
journal = {Asian journal of transfusion science},
year = {2026},
month = jun,
doi = {10.4103/ajts.ajts_90_25},
url = {https://europepmc.org/article/MED/42953491},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A prospective study on the prevalence of neonatal alloimmune thrombocytopenia with maternal and neonatal human platelet antigen genotypic profiling.
AU - Greeshma Sharma
AU - Ratti Ram Sharma
AU - Praveen Kumar
AU - Rekha Hans
AU - Prateek Bhatia
AU - Shano Naseem
AU - Divjot Singh Lamba
PY - 2026
DA - 2026/06/02
JO - Asian journal of transfusion science
DO - 10.4103/ajts.ajts_90_25
UR - https://europepmc.org/article/MED/42953491
AB - Neonatal alloimmune thrombocytopenia (NAIT) results due to the human platelet antigen (HPA) incompatibility between the mother and the fetus, which in turn leads to maternal alloimmunization against fetal platelet antigen. In view of the lack of a defined protocol for its diagnosis and management, it is important to identify at-risk patients with the help of new noninvasive methods and prevent fetal complications. The aim of our study was to evaluate the suspected cases of NAIT so as to determine its prevalence and formulate an appropriate algorithm for its diagnosis and management in our setup. Thrombocytopenic neonates from neonatal services were included in the study between May 2018 and March 2020. An algorithm was designed to evaluate the suspected cases of NAIT, which involved the clinical assessment of the neonate and maternal HPA antibody screening and compatibility test with the neonatal platelet antigens by maternal serum on a solid phase red cell adherence assay system by Immucor, Norcoss A, USA. In addition, genotypic analysis was done to find out the implicated HPA antigens present in the neonate, causing NAIT. The genotypic assessment was done using the Link Seq HPA Typing Kit, by One Lambda, and real-time polymerase chain reaction. Out of 6237 neonates screened for eligibility, we found 1143 neonates to be thrombocytopenic. Out of 1143 thrombocytopenic neonates, we diagnosed NAIT in 10 neonates, giving a prevalence of 0.8% in thrombocytopenic neonates and 0.16% in the total enrolled neonates. The prevalence of NAIT in neonates with thrombocytopenia was 0.8%, and 0.16% in the total admitted neonates. HPA-3b, Hpa-9b and HPA-15b were found to be the most commonly implicated antigens leading to thrombocytopenia in the neonates, in our population.
SN - 0973-6247
SN - 1998-3565
ER -